Oct 5, 2020

Featuring a discussion on recent advances in the use of PARP inhibitors in breast cancer with Dr Susan Domchek, including the following topics:

• PARP Inhibitors in Breast Cancer — Susan M Domchek, MD (00:00)
• Case: A woman in her early 40s with ER-positive metastatic breast cancer and a BRCA2 mutation receives olaparib after experiencing disease progression on fulvestrant/palbociclib (20:31)
• Case: A woman in her early 30s with triple-negative breast cancer and a BRCA1 mutation is enrolled on the OlympiA trial (28:18)

CME information and select publications